Objectives: To explore the occurrence and characterization of carbapenemaseproducing pathogens among carbapenem-resistant Gram-negative bacilli isolated from hospitalized patients with urinary tract infection in Indonesia.
Introduction
UTI caused by CR bacteria often leads to treatment failure or a poor prognosis. 1, 2 One of the principal mechanisms for carbapenem resistance is the production of b-lactamase, which hydrolyzes most b-lactams. 3 There are many kinds of b-lactamases. Bush et al. described 17 kinds of b-lactamases, which include ESBL, such as CTX-M; AmpC b-lactamase, such as DHA, ACT, and carbapenemases such as IMP, NDM, KPC, VIM and OXA. [2] [3] [4] [5] IMP, NDM and VIM are called as MBLs. 3 ESBLs hydrolyze penicillins and cephalosporins, whereas carbapenemases hydrolyze carbapenems and other blactams. b-lactamase class subgroup 2be, known as ESBL, was the most prevalent in Indonesia, until clinicians shifted to carbapenem as the antibiotic of choice. The other main mechanism is the changes in the bacterial cell wall to inhibit the entry of carbapenem into the bacterial cell. A more newly discovered efflux pump was also identified, where carbapenem can enter the cell, but is quickly flushed out by the bacterial efflux system.
The diagnosis of CR-GNB is necessary as early as possible for effective patient care. The phenotypic and genotypic features of CP CR-GNB need to be investigated to trace the global dissemination, to understand epidemiology and to optimize antibiotic use. Although such surveys need to be carried out in every region of the world, importantly, some regions have limited research clinical facilities. 6 The present study focuses on CR-GNB through the international collaboration between Japan and Indonesia through the J-GRID project supported by AMED. 1 The J-GRID project aims to mitigate the risk of infectious diseases, including antibioticresistant bacteria, by international collaboration. A recent survey of eight Indonesian hospitals in 2016 (not yet published) showed that the occurrence of ESBL among Escherichia coli and Klebsiella pneumoniae (the most prevalent ESBL producers) ranged between 46% to 85%. Data from 2010 in three cities in Indonesia showed that 45% of E. coli and K. pneumoniae seen were ESBL-producing, and that of 2014 showed a higher rate. 7, 8 ESBL-producing bacteria are resistant to the third-generation cephalosporin and monobactam/AZT, and in Indonesia the choice of antibiotics is limited to carbapenem, AMK, the combination of the third-generation cephalosporin with b-lactamase inhibitors (S/C and PIPC/TAZ), FOM and TGC. 7 The purpose of the present study is to explore the phenotypic and genotypic characteristics of CR-GNB isolated from urine specimens from hospitalized patients with suspected UTI in Dr. Soetomo Hospital, Surabaya, Indonesia, through the Japanese-Indonesian research collaborative program in J-GRID. 1 
Methods

Study design
The present prospective study was carried out from 12 September 2015 to 29 April 2016 in the Clinical Microbiology Laboratory of Dr. Soetomo Hospital, Surabaya, Indonesia, a 1500 bed tertiary referral hospital with 26 departments. Urine cultures collected by the Clinical Microbiology Laboratory at Dr. Soetomo Hospital, were derived from a variety of wards (medical or surgical or others) in this hospital. This study was approved by the ethical committee in health research of Dr. Soetomo Hospital, Surabaya (No. 20/Panke. KKE/I/2016) and Kobe University Graduate School of Health Sciences (No. 393) as a multicenter study. Informed consent was obtained by explaining the study directly to the patients, followed by the signature of the patient or his/her responding family in cases involving children or non-responsive patients. All experiments were carried out in compliance with the relevant laws and guidelines in accordance with the ethical standards of the Declaration of Helsinki. All 22 elements of the Strengthening the Reporting of Observational Studies in Epidemiology statement have been accommodated. The present study was carried out through the Japanese-Indonesian research collaborative program in J-GRID. 1 
Bacterial identification and antimicrobial susceptibility testing
A total of 700 GNB resistant to at least one-third generation cephalosporin and/or resistant to IPM or MEPM were collected from urine specimens. All samples were 1 lL, acquired with a special disposable loop and inoculated on blood agar and MacConkey agar, and incubated at 37°C overnight. If results were negative, incubation was extended for 2 days.
A specimen was considered positive for UTI if one or more organisms were cultured at a concentration of ≥10 5 CFU/mL or 10 4 CFU/mL with a significant clinical diagnosis by clinicians. After that, bacterial identification and antimicrobial susceptibility testing was carried out by the broth microdilution method using a BD Phoenix Automated Microbiology System (Phoenix-100; Becton Dickinson Indonesia, Jakarta, Indonesia) according to the manufacturer's standard protocols. E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were included by the routine procedure as a quality control. The isolates were then inoculated into a trypticase soy broth supplemented with 16% glycerin and stored at À80°C. The isolates were re-tested at the Kobe University Faculty of Health Sciences, Japan, for further detection of CP bacteria. Three panels were used for detection of Gram-negative bacteria (BD Phoenix NMIC/ID Panels for MIC and identification, BD Phoenix NMIC Panels for MIC and BD Phoenix NID Panels for identification).
Antimicrobial susceptibility was tested by the broth microdilution method for the following 19 antibiotics: AMK, AZT, CFPM, CAZ, CPFX, CL, DRPM, FOM, GM, IPM, LVFX, MEPM, MINO, PIPC, PIPC/TAZ, S/C, TGC, TOB and TMP/SMX according to CLSI guidelines, 9 except for TGC. The European Committee on Antimicrobial Susceptibility Testing (www.EUCAST.org) criteria were used for TGC of Enterobacteriaceae. The breakpoint of P. aeruginosa and Acinetobacter spp. for TGC representatively used that for Enterobacteriaceae as the reference. The S/C breakpoint was based on that of cefoperazon according to the CLSI guideline, 9 and FOM susceptibility was presented as MIC 90 , as in previous studies. 10 Isolated GNB was considered as CR-GNB if they were found non-susceptible to one or more of the carbapenems (DRPM, IPM and MEPM). Antimicrobial sensitivity for DRPM, IPM and MEPM were defined as follows: resistant, MIC ≥4 lg/mL; intermediate, MIC = 2 lg/mL; susceptible: MIC ≤1 lg/mL (for Enterobacteriaceae) and resistant, MIC ≥8 lg/mL; intermediate, MIC = 4 lg/mL; and susceptible, MIC ≤2 lg/mL (for P. aeruginosa and Acinetobacter spp.) according to CLSI guidelines.
Molecular analysis of ESBL, AmpC and carbapenemase genes using MLST
To investigate ESBL and AmpC genes, PCR was carried out, as in previous studies.
11 -14 To investigate carbapenemase genes including NDM-1, IMP-7 and OXA-181, multiplex PCR (Hyplex SuperBug ID; Amplex, Gars am Inn, Germany) was used. This system can identify the phenotype of carbapenemase genes, such as bla VIM (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , bla IMP and bla NDM-1 ; oxacillinase genes, such as bla OXA-48 -like encoding genes (including bla OXA-162 , OXA-181 , OXA.204 and bla OXA-244 ); and all variants of bla KPC(1-10) genes, as previously described. 15 DNA sequencing was carried out by Eurofins Genomics, Tokyo, Japan, after purification of PCR products by the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). Primer setting and analyses for the MLST of each bacteria were based on the pubMLST Databases (https://pub mlst.org/) and determined the sequence type.
Phenotypic methods for detecting carbapenemase activity and ESBL production
The Modified Hodge test was used to screen for carbapenemase production using DRPM, IPM and MEPM according to CLSI guidelines. 9 MBL production was investigated with an MBL antimicrobial gradient test using IPM and IPM/EDTA E-test MBL strips (bioM erieux, Lyon, France). A ratio of MIC IPM /MIC IPM/EDTA ≥8 is considered presumptive of MBL. ESBL production was evaluated by CLSI screening and confirmatory test methods. 9 
Evaluation of clinical conditions
Clinical outcomes were evaluated according to criteria as follows: results of treatment at the time of discharge: good = fully cured; better = better than the time of admission; bad = worse. The outcomes were a clinical judgment by the doctor in charge (clinician) based on Indonesian national guidelines from the Ministry of Health, Indonesia, Ministerial decree No. 5/2014: Clinical Guideline for Medical Doctor in Primary Health Care. Prognosis consisted of four groups: cure, better, bad and dubious (could be better or worsening) as follows: cure = cured and normal physiologically; better = improved, but still not fully cured; bad = not cured and could be worsening; dubious = could be better or worse, difficult to predict by Medical Prognosis (http://survinat.com/2012/05/medical-prognosis/, accessed 16 May 2018). Data were extracted from the medical records written down by the doctor in charge, according to the professional practices in Indonesia.
Results
Urine isolates
A total of 4861 urine samples from UTI patients were collected, of which 1318 (27.1%) showed bacterial growth, and as many as 1082 (82.1%) showed GNB. A total of 700 isolates (64.7%) of GNB resistant to one or more third-generation cephalosporins and/or carbapenems in 1082 GNB were identified and all were collected. Among the 700 isolates, 338 
CR-GNB and CP-GNB isolates
Of the 700 isolates, 116 (16.6%) were intermediate or resistant against IPM or MEPM as CR-GNB; of these, 22 (19%) out of 116 isolates were CP-GNB (Table 1) , for a CP-GNB of 2.03% (95% CI 1.192-2.874) against 1082 GNB. This suggests the gradual increase of CR strains supported by previous literature reporting 5.8% were CR strains, 6 which should be taken as an early warning for hospitals in Indonesia. 7, 16, 17 
ESBL and AmpC genes
Among the 22 strains of CP-GNBs, four strains produced ESBL. The distribution was two strains in five K. pneumoniae P. aeruginosa IMP-7 ST622 †Extended-spectrum b-lactamase. ‡"Non-type" was not typed by MLST. A. baumannii: gltA-gyrB-gdhB-recA-cpn60-gpi-rpoD = 28-38-45-1-16-100-2.
§"Non-data" means no database for the bacteria.
(40%), one in two E. cloacae (50%) and one in four P. rettgeri (25%). The ESBL types were TEM-1 (3/4; 75%), CTX-M-15 (2/4; 50%) and SHV-12 (1/4; 25%; Table 1 ). Of 22 strains, two strains with AmpC included one strain in the two E. cloacae (50%), and one in the four P. rettgeri (25%). The AmpC types were ACT (1/2; 50%) and DHA (1/2; 50%).
Carbapenemase phenotypes and MLST
Carbapenemase phenotypes were as follows: 18 strains (81.8%) of NDM-1, four strains (18.2%) of IMP-7 and one strain (4.6%) of OXA-181. All four strains of IMP-7 were from P. aeruginosa (Table 1 ). In the results of MLSTs, ST273 and ST307 were seen in ESBL-producing K. pneumoniae (Table 1 ). ST307 was detected in two different K. pneumoniae isolates. ST1000 and ST1089 were seen in A. baumannii. ST78 and ST121 were seen in E. cloacae. ST622 were seen in all of P. aeruginosa. One strain of A. baumannii was not typed in the pubMLST database.
A. baylyi, A. junii, C. lapagei and P. rettgeri do not have available data in the pubMLST database.
Antibiotic susceptibilities
Among the 22 isolates of CP-GNB, CL could cover all CP-P. aeruginosa and Acinetobacter spp. (100% susceptibility), and Enterobacteriaceae with 66.7% susceptibility ( Table 2 ). The six strains of Acinetobacter spp. had better susceptibility to MINO and TGC with 100% susceptibility, and less susceptibility to GM, TOB and TMP/SMX with 50% susceptibility. FOM with MIC 90 = 128 lg/mL was for P. aeruginosa. These results suggest that some antibiotics can cover UTI caused by CP-GNB. Table 3 shows the clinical condition of the 22 patients with CR-GNB. All were inpatients. A total of 10 (45.5%) cases were diagnosed as moderate and 12 (54.5%) as severe. The physical condition of the patients on admission were categorized as good (n = 0, 0%), moderate (n = 13, 59.1%), weak (n = 6, 27.3%) and bad (n = 3, 13.6%), meaning that most patients were not in good condition and the risk of infection was higher. The average length of hospital stay among these patients was 39.5 days (6-108 days), longer than the average stay in this hospital (7.68 days) .
Clinical condition of 22 patients with CR-GNB isolated from urine specimens
Patient outcomes at the time of discharge were as follows: good or fully cured (n = 1, 4.5%), better (n = 17, 77.3%), bad (n = 1, 4.5%) and died (n = 3, 13.6%). The prognosis of the 19 discharged patients were: cure (n = 3, 15.8%), better (n = 6, 31.6%), dubious (n = 2, 10.5%) and bad (n = 8, 42.1%) patients. Thus, most discharged patients had the risk of worsening of their diseases and had a high possibility of re-admission to the hospital ( Table 3) .
The antibiotics used were CRO in 15 (68.2%) patients, MTZ in seven (31.8%), aminoglycoside in six (27.3%), quinolone in four (18.2%), penicillin with b-lactamase inhibitors, CAZ and MEPM in each of three (13.6%), and cefixime, FLUCO and TMP/SMX in each of one (4.6%) including poly-antimicrobial therapy as follows. One patient used four kinds of antibiotics during their hospital stay, followed by eight patients who used three kinds of antibiotics and nine patients who used two kinds of antibiotics (Table 3) .
Discussion
We showed 64.7% of Gram-negative rods were resistant to one or more third-generation cephalosporins and/or carbapenem, and 16.6% were resistant to IPM or MEPM (CR-GNB). This indicates the CR strains are increasing in Indonesia. 7, 16, 17 We detected 2.03% of all UTI-causing GNB from Surabaya, Indonesia as CP-GNB. Of these strains, CPE accounted for 12 (1.1%) of a total 1082 GNB, or 10.3% of the 116 CR-GNB. CP-P. aeruginosa and Acinetobacter spp. accounted for eight (0.74%) of the total GNB, or 6.9% of the total 116 CR-GNB (Table 1 ). Other studies have found UTI-causing CRE to be between 1.4-4.2% in the USA, 18 1.2% in Lebanon, 4.05% in Malaysia, <1% in Singapore, 1.2% in Taiwan and 1.17% in Saudi Arabia. 19 The present study showed that 2.4% of 4861 urine specimens and 10.7% of 1082 Gram-negative isolates were CR-GNB, comparable with other countries. Among them, 22 (0.45%) were CP-GNB, or 19% among CR-GNB and 2% of all Gram-negative isolates. Ohno et al. from Japan found 17 (0.34%) of 4875 isolates were CPE. 20 The present study partly differs from studies in Japan. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Koyano et al. found that 13 (0.8%) of 1704 isolates from Tokyo were CPE, and mostly dominated by the IPM-1 gene (n = 12, 92.3%). 21 A study from another city in Japan showed that 20 CPE were included in two STs (ST2 and ST246), and 17 (85%) were bla OXA-23 type, 22 24 Interestingly, a recent study in Jakarta, the capital city of Indonesia, showed that all 14 carbapenem non-susceptible isolates from an ICU harbored the OXA gene (13 OXA-66 and one OXA-68). 25 NDM-1-producing Enterobacteriaceae might carry other mechanisms for antibiotic resistance with various b-lactamases and other types of carbapenemases resistant to other antimicrobials. 19 We found that 18 strains with bla NDM-1 were susceptible to MINO, TMP/SMX and TGC than P. aeruginosa strains with bla IMP-7 . These findings may be relevant to treatment, and also call for further explanatory and mechanistic research.
We found three kinds of ESBL genes in four ESBL-positive strains and two AmpC-positive strains. CTX-M-15 was involved with TEM-1 or AmpC DHA. Baran et al. isolated CRE having co-producing carbapenemase (bla NDM -1 and bla OXA-48 ) and ESBL. 19 We found that ESBL-producing strains were still susceptible to CL and TGC.
Yamamoto et al. showed that ST42 was predominant in NDM-1-positive K. pneumoniae from UTI patients in Japan. 26 OXA-48-positive K. pneumoniae had four major clones: ST11, ST15, ST16 and ST405.
27 ST357 has been observed among IMP-7-positive P. aeruginosa in Central Europe. 28 We showed that, even though only a small number of strains and varieties of sequence types were observed, ESBL-positive K. pneumoniae (NDM-1) had ST273 and ST307. The nontype strain of A. baumannii had no presence in the database and would be a new type in Indonesia. Our detected NDM strains were dominant in Indonesia and common in other countries, suggesting that this type is widespread worldwide. We found that UTI-causing CP-GNB were susceptible only to CL (susceptible rate: 81.8%) and TGC (40.9%), suggesting that carbapenem resistance is accompanied by resistance to other antibiotics. Other studies showed these antibiotics still have some effectiveness, 29, 30 but the present study showed that TGC was less effective on bla IMP-7 -positive P. aeruginosa, and CL was less effective on bla NDM-1 -positive P. rettgeri. All six CP Acinetobacter spp. were susceptible to CL, TGC and MINO, and all four CP-P. aeruginosa were susceptible to CL, but not to TGC. Lolans et al. reported that bla OXA-40 correlated with non-susceptibility to TGC in CR-A. baumannii in the USA. 31 Patients with CP-GNB had much longer than average stays in hospital. Saharman et al. in Jakarta, Indonesia, reported that the isolation rate of CR-A. baumannii in the ICU increased alongside the length of hospitalization up to 22 days. 24 This suggests that longer hospitalization increases the risk of transmission of CR-bacteria. The present study showed 13.6% cases of CP-GNB-causing The result of the treatment at the time of discharge, good: fully cured; better: better than the time of admission; bad: worse. ‡Prognosis: the prognosis was assessed by the doctor in charge at the time of discharge, cure: cured and normal physiologically; better: improved but still not fully cured; bad: not cured and could be worsening; dubious: could be better or worse, difficult to predict.
infectious diseases died. Up to 34 kinds of antibiotics per patient were consumed for those patients. The risk factors for carbapenem resistance, including mechanisms described above, include longer hospital stay, more use of antibiotics and the seriousness of the disease. 24, 32 Recently, as internationalization is rapidly progressive, this kind of international collaboration has been increasing. 1, 39 Basically, as many scientists know, infectious diseases and research vary among countries owing to the difference of antibiotic use, and the environment of not only education, but living and medical systems. 1, 16, 33 However, importantly, this kind of variation among countries is not so well-recognized, so such measures for improving infection-related matters mentioned above might not be fully undertaken. The present study can be one of such clues that overcome those problem through a global international collaboration system mentioned in the study purpose.
We would like to emphasize the study limitations. First, the number of isolates was small and more CP-GNB strains need to be investigated. Second, our MLST data included some undetermined data. Third, another mechanistic studies are lacking, for instance, on bacterial porin or efflux pump. Fourth, full clinical data were not available for investigation. Further studies are required to advance this field of research.
In conclusion, we detected 22 (2.03%) CP-GNB strains in 1082 consecutive specimens isolated of GNB from UTI in one general hospital in Indonesia in 8 months. bla NDM -1 was dominant among CRE, but bla IPM-7 was dominant in P. aeruginosa. CP-Acinetobacter spp. strains showed good susceptibilities to CL and TGC, whereas CP-P. aeruginosa showed good susceptibility to CL not to TGC.
